Ampudia-Blasco FJ - Search Results

1

[Dapagliflozin, the first SGLT-2 inhibitor in the treatment of type 2 diabetes].

Albarrán OG, Ampudia-Blasco FJ. Albarrán OG, et al. Med Clin (Barc). 2013 Sep;141 Suppl 2:36-43. doi: 10.1016/S0025-7753(13)70062-9. Med Clin (Barc). 2013. PMID: 24444523 Review. Spanish.

2

[Cardiovascular disease in diabetes mellitus].

Ampudia-Blasco FJ, Navarro J. Ampudia-Blasco FJ, et al. Med Clin (Barc). 2002 Mar 9;118(8):306-11. doi: 10.1016/s0025-7753(02)72367-1. Med Clin (Barc). 2002. PMID: 11888500 Review. Spanish. No abstract available.

3

[Importance of daily glycemic variability in achieving glycemic targets in type 2 diabetes: role of DPP-4 inhibitors].

Ampudia-Blasco FJ, Ceriello A. Ampudia-Blasco FJ, et al. Med Clin (Barc). 2010 Sep;135 Suppl 2:33-9. doi: 10.1016/S0025-7753(10)70031-2. Med Clin (Barc). 2010. PMID: 21420536 Review. Spanish.

4

Efficacy and safety of empagliflozin in combination with other oral hypoglycemic agents in patients with type 2 diabetes mellitus.

Romera I, Ampudia-Blasco FJ, Pérez A, Ariño B, Pfarr E, Giljanovic Kis S, Naderali E. Romera I, et al. Endocrinol Nutr. 2016 Dec;63(10):519-526. doi: 10.1016/j.endonu.2016.06.003. Epub 2016 Aug 28. Endocrinol Nutr. 2016. PMID: 27578024 English, Spanish.

5

Two clinical cases of adjunctive use of a SGLT-2 inhibitor in type 1 diabetes.

Siegmund T, Ampudia-Blasco FJ, Schnell O. Siegmund T, et al. Diabetes Res Clin Pract. 2020 Apr;162:108131. doi: 10.1016/j.diabres.2020.108131. Epub 2020 Mar 29. Diabetes Res Clin Pract. 2020. PMID: 32234505

6

Efficacy and safety of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index ≥ 27 kg/m².

Danne T, Edelman S, Frias JP, Ampudia-Blasco FJ, Banks P, Jiang W, Davies MJ, Sawhney S. Danne T, et al. Diabetes Obes Metab. 2021 Mar;23(3):854-860. doi: 10.1111/dom.14271. Epub 2020 Dec 23. Diabetes Obes Metab. 2021. PMID: 33289297

7

[Selective therapeutic embolization in malignant insulinoma].

Civera Andrés M, Real Collado JT, Martínez Usó I, Ampudia Blasco FJ, Carmena Rodríguez R. Civera Andrés M, et al. Rev Clin Esp. 2000 Oct;200(10):548-50. doi: 10.1016/s0014-2565(00)70718-1. Rev Clin Esp. 2000. PMID: 11153238 Spanish.

8

[Estimated prevalence of chronic renal failure among patients with type 2 diabetes in Spain].

de Pablos-Velasco PL, Ampudia-Blasco FJ, Cobos A, Bergoñón S, Pedrianes P; en representación del Grupo de Investigadores DIABIR. de Pablos-Velasco PL, et al. Med Clin (Barc). 2010 Mar 20;134(8):340-5. doi: 10.1016/j.medcli.2009.09.045. Epub 2009 Dec 29. Med Clin (Barc). 2010. PMID: 20036403 Spanish.

9

Basal plus basal-bolus approach in type 2 diabetes.

Ampudia-Blasco FJ, Rossetti P, Ascaso JF. Ampudia-Blasco FJ, et al. Diabetes Technol Ther. 2011 Jun;13 Suppl 1:S75-83. doi: 10.1089/dia.2011.0001. Diabetes Technol Ther. 2011. PMID: 21668340 Review.

10

A decision support tool for appropriate glucose-lowering therapy in patients with type 2 diabetes.

Ampudia-Blasco FJ, Benhamou PY, Charpentier G, Consoli A, Diamant M, Gallwitz B, Khunti K, Mathieu C, Ridderstråle M, Seufert J, Tack C, Vilsbøll T, Phan TM, Stoevelaar H. Ampudia-Blasco FJ, et al. Diabetes Technol Ther. 2015 Mar;17(3):194-202. doi: 10.1089/dia.2014.0260. Epub 2014 Oct 27. Diabetes Technol Ther. 2015. PMID: 25347226 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

71 results

Search Page

Filters